1.
Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner C-M, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. haematol [Internet]. 2021Jun.17 [cited 2022Jun.27];107(2):500-9. Available from: https://haematologica.org/article/view/haematol.2020.274803